Show simple item record

dc.contributor.authorRASMUSSEN, S.
dc.contributor.authorGARBER, A. J.
dc.contributor.authorBHARGAVA, A.
dc.contributor.authorDHARMALINGAM, M.
dc.contributor.authorSKJOTH, T. V.
dc.contributor.authorSatman, I.
dc.contributor.authorPHILIS-TSIMIKAS, A.
dc.contributor.authorDEL PRATO, S.
dc.date.accessioned2021-03-05T22:00:33Z
dc.date.available2021-03-05T22:00:33Z
dc.date.issued2013
dc.identifier.citationPHILIS-TSIMIKAS A., DEL PRATO S., Satman I., BHARGAVA A., DHARMALINGAM M., SKJOTH T. V. , RASMUSSEN S., GARBER A. J. , "Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents", DIABETES OBESITY & METABOLISM, cilt.15, ss.760-766, 2013
dc.identifier.issn1462-8902
dc.identifier.othervv_1032021
dc.identifier.otherav_db8d8eb9-bc3c-436f-989c-6efe6880bfe2
dc.identifier.urihttp://hdl.handle.net/20.500.12627/144726
dc.identifier.urihttps://doi.org/10.1111/dom.12115
dc.description.abstractAim: The efficacy and safety of insulin degludec (IDeg), a new basal insulin with an ultra-long duration of action, was compared to sitagliptin (Sita) in a 26-week, open-label trial.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.titleEffect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
dc.typeMakale
dc.relation.journalDIABETES OBESITY & METABOLISM
dc.contributor.departmentScripps Whittier Diabet Inst , ,
dc.identifier.volume15
dc.identifier.issue8
dc.identifier.startpage760
dc.identifier.endpage766
dc.contributor.firstauthorID17929


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record